Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 7 of 7 results for lymphopenia

  1. Radiation-induced lymphopenia and risk of new COVID-19 and severity of COVID-19: Does radiation-induced lymphopenia predispose patients to an increased risk of new COVID-19 and does it contribute to patients developing more severe COVID-19?

    Question Radiation-induced lymphopenia and risk of new COVID-19 and severity of COVID-19: Does radiation-induced...

    Research recommendation
    Published
    21 October 2021

  2. Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)

    Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    6 September 2017
    View recommendations

    Sections for TA475

  3. Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)

    Evidence-based recommendations on carmustine implants (Gliadel) and temozolomide for treating newly diagnosed high-grade glioma in adults.

    Technology appraisal guidance
    Published
    27 June 2007
    View recommendations

    Sections for TA121

  4. Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

    Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    27 August 2014
    View recommendations

    Sections for TA320

  5. Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

    Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.

    Technology appraisal guidance
    Published
    21 December 2016
    View recommendations

    Sections for TA421

  6. Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA763

  7. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

    Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA412